Charles River Laboratories (CRL) Q3 2026 earnings review
Charles River drug testing accelerates, while its animal unit shrinks
Charles River Laboratories, a provider of research animals and drug-testing services, turned its recent order recovery into revenue growth while shedding weaker units lifted profitability. Sales from businesses owned a year ago rose 5%, beating the company's 1% to 3% plan as drug safety testing accelerated. Chief executive Birgit Girshick raised the full-year outlook across the board, and a foreign tax law change released $246 million of acquired tax reserves.
| Sales from businesses owned a year ago | +4.7% 1.0% to 3.0% planned |
|---|---|
| Operating margin, excluding one-offs | 23.0% +3.3 percentage points from a year ago |
| Profit per share, excluding one-offs | $3.09 +27% from a year ago |
| Full-year underlying sales outlook | Raised 1 point to at least +1.5% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the three quarters of rising drug-safety orders are now showing up in lab volume and operating margins, while a feared foreign tax hit flipped into a reserve release. One caution: the Research Models unit shrank again on weak North American demand for small animals, and the company raised its estimate of full-year restructuring charges to $1.50 per share.
The question now is whether rising drug-testing volume is the start of a multi-year recovery or a catch-up wave that computer-based testing will cap. If biotech clients keep starting new trials, safety-testing orders will stay above revenue and bring pricing power in 2027; if non-animal virtual control groups replace live studies, volume growth will stall. Fourth-quarter booking disclosures and 2027 targets will show which path holds.
🐂 Bull Case
Drug Safety Testing Volume Accelerates
Charles River provides laboratory animals and preclinical testing for drugmakers. Discovery and Safety Assessment (DSA), its largest unit that runs regulated safety trials before human testing, returned to real growth. "In the third quarter, we were encouraged by the continued strength of the biopharmaceutical demand environment and that was reflected in our financial results," chief executive Birgit Girshick said.
- Total sales from businesses owned a year ago: up 4.7%, beating the 1.0% to 3.0% outlook
- DSA underlying sales: up 5.9%, after 0.2% growth last quarter and a 3.1% drop a year ago
- Manufacturing Solutions underlying sales: up 7.4%, led by biologics and microbial testing
This matters because the three quarters of rising customer orders since late 2025 are now turning into laboratory work. Even accounting for an easy comparison against last year's slump, the 5.9% jump in safety testing shows biotech clients are starting trials again. Girshick added that "DSA net bookings and proposals continued to show robust, year-over-year increases", although the release did not print the exact order-to-sales ratio.
What to watch: the exact DSA order-to-sales ratio and backlog total on the conference call or in the quarterly filing. A reading above 1.0 times sales for a fourth straight quarter would confirm that the recovery extends into 2027.
Selling Weak Units Lifted Operating Margins
The preclinical testing company sold its contract manufacturing (CDMO), Cell Solutions, and European discovery sites in May 2026. This quarter was the first full period without those money-losing and lower-margin operations. Operating margin excluding one-offs rose 3.3 percentage points from a year ago to 23.0%, beating the company's plan by 0.5 points.
By our math, the cost of providing services and making products fell 2.7 percentage points of revenue to 63.6%, while selling and overhead costs before adjustments dropped 3.4 points to 14.3%. In Manufacturing Solutions, the unit that checks drug purity, operating margin excluding one-offs jumped 11.9 points to 38.6% after the CDMO exit. In DSA, margin rose 1.4 points to 26.8% on "higher study volume for regulated safety assessment services" and "lower sourcing costs for large research models" from its newly acquired Cambodian primate supplier.
What to watch: fourth-quarter DSA operating margin when lower-cost internally sourced primates reach full study use. By our math, the full-year profit outlook requires fourth-quarter profit per share excluding one-offs to reach $3.28 at the middle of the range, up from $3.09 this quarter.
Foreign Tax Law Change Reverses a Liability
When Charles River bought its Cambodian primate supplier in January, it took on more than $200 million in uncertain tax liabilities. Last quarter, management also warned that proposed foreign tax laws could raise its full-year tax rate and cut profit by $0.20 per share. Both tax worries moved in the company's favor this quarter.
The company recorded a $245.6 million gain, or $5.06 per share, from the "reversal of acquired tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction". That included $44.6 million of non-income tax reserves inside the DSA unit and $201.1 million of income tax reserves. In addition, the company said a lower ongoing tax rate helped drive its $0.15 raise to the full-year profit per share outlook excluding one-offs.
What to watch: the remaining balance of uncertain tax liabilities in the third-quarter filing's tax footnote. A sharp drop in that liability would show that the K.F. Cambodia acquisition tax overhang is mostly settled.
🐻 Bear Case
Research Models Unit Still Shrinks in North America
Girshick wants to "increase our share of R&D spend as demand trends continue to improve", and she pointed to broad biopharmaceutical strength. Yet Research Models and Services (RMS), the unit that breeds mice, rats, and primates for early research labs, failed to grow again. Underlying sales in RMS fell 0.6% from a year ago, marking a third straight quarter of contraction.
Charles River blamed "lower revenue for small research models in North America and for large research models", which outweighed growth in China and in its lab-staffing service. Operating margin excluding one-offs in the unit slipped 0.6 percentage points to 24.4% because of an "unfavorable revenue mix, both geographically and related to large research models". Early discovery labs in North America are still tight with their budgets even as late-stage preclinical trials pick up.
What to watch: North American small-animal volume and pricing in the fourth quarter. Continued contraction there would mean early-stage academic and biotech research is not joining the broader recovery.
Computer Models Are Entering Regulated Drug Trials
Animal-based safety testing in DSA brings in 61% of Charles River's revenue, so regulators' push toward non-animal testing methods is a major long-term risk. To keep up, the group runs its Alternative Methods Advancement Project (AMAP), a program to develop computer and cell-based tests. This quarter brought concrete steps showing that those tools are moving into regulated drug development.
The US company announced that its Virtual Control Group (VCG) database — software that uses historical data in place of live control-group animals — will be used in an upcoming Good Laboratory Practice safety study for drugmaker Ipsen. It also partnered with the US Food and Drug Administration to "validate preclinical screening tools to quantify and rank the abuse potential of new drugs". While Charles River is building these tools itself, every virtual control group reduces the number of animals and lab staff needed for a study.
What to watch: revenue per study in the Ipsen virtual control trial and future AMAP disclosures. If virtual controls shrink the dollar value of a safety study faster than they bring in new software fees, they will weigh on DSA growth.
One-Off Charges Still Cut Reported Profit
Without the $5.06 per share tax reserve release, reported profit per share this quarter was $1.80 by our math, $1.29 below the $3.09 figure excluding one-offs. For the full year, the company raised its estimate of restructuring and efficiency charges by $0.30 to about $1.50 per share, alongside $4.70 per share in acquisition and divestiture costs and $2.10 in amortization. Meanwhile, several standing risks and watch items were not updated in the release:
- Fourth-quarter profit weighting: the full-year outlook implies $3.18 to $3.38 per share in Q4 by our math, relying on Cambodian primate cost savings arriving on schedule.
- DSA order-to-sales ratio: Girshick said bookings grew, but the exact ratio and backlog total wait for the call or filing.
- Primate import rules and legal overhang: no update in the release on the $105 million contingent payment for K.F. Cambodia or the shareholder lawsuit over past primate imports.
What to watch: restructuring cash outflows in the 2027 outlook next quarter. If site-closure charges stay above $1.00 per share for a fourth year, they are a normal cost of running the business rather than a one-off.
👓 Other Themes
Investor Day and Lab Automation Rollout
At its September Investor Day, Charles River presented its Pathway to Purpose strategy and a modernization program it calls Create the Future. During the quarter, it opened an automated manufacturing suite for its Endosafe bacterial-toxin test cartridges and partnered with Autolomous to launch Apollo Orchestrate, software that digitizes lab workflows. It also added DNA sequencing to its cell banking service to "significantly accelerate product release timelines in its Biologics Testing Solutions business".
💲 Other KPIs
Up 16.8% from a year ago and up from $148.6 million last quarter, by our math from the nine-month cash flow statement. Free cash flow is operating cash after capital spending; it rebounded in the third quarter to 21.1% of revenue after bonus and deal payments weighed on the first half.
Down $176.5 million from $2,620 million last quarter, as the company used third-quarter cash flow to pay down credit lines after borrowing in the first half for acquisitions. By our math, debt minus cash fell 7.6% from last quarter to $2,243 million.
Down 1.7% from 49.4 million a year ago because of $324.1 million in stock buybacks over the first nine months of 2026. The company spent almost nothing on buybacks in the third quarter after repurchasing $300 million in the first half, directing cash toward debt reduction instead.
🔮 Guidance
Raised. Management lifted the full-year outlook by 1.0 percentage point after the third-quarter beat in safety testing. By our math, with underlying sales up 1.0% over the first nine months, the new floor leaves at least 3.0% growth for the fourth quarter, compared with a 2.6% decline in the fourth quarter of last year.
Raised. The middle of the range moved up 1.25 percentage points to a 1.75% decline, matching the stronger underlying sales plan while keeping the 4.5-point drag from May's divestitures unchanged. By our math, that leaves a 3.2% reported revenue drop for the fourth quarter.
Raised. The middle of the range rose $0.15 to $11.45, or 11.4% growth over 2025. It is the third raise this year: +$0.10, +$0.25, +$0.15. By our math, subtracting the first three quarters ($8.17 in total) leaves $3.28 for the fourth quarter at the middle of the range, up 37.2% from $2.39 a year ago.
Raised. The middle of the range jumped $5.05 to $8.25, driven by the $5.03 per share full-year benefit from reversing acquired foreign tax reserves. Restructuring charges inside the bridge rose by $0.30 to about $1.50 per share, offset by $0.20 lower amortization.
❓ Key Questions
What was the exact DSA order-to-sales ratio in Q3?
Girshick said safety-testing net bookings and proposals rose strongly from a year ago, but the release omitted the exact book-to-bill ratio and backlog dollar figure after reporting 1.19 times and $1.97 billion last quarter.
How much did Cambodian primates lift Q3 DSA margin?
DSA margin excluding one-offs rose 1.4 percentage points to 26.8% on volume and lower primate costs. Investors need to know how many basis points came from internal primate supply in Q3 versus what remains for Q4.
Does the foreign tax release settle the K.F. Cambodia liability?
Charles River reversed $245.6 million of acquired tax reserves after foreign tax law changes. Did this wipe out the $233 million uncertain tax liability assumed in the K.F. Cambodia acquisition, and what changed in the law?
Why did full-year restructuring charges rise another $0.30 per share?
The company lifted its 2026 restructuring cost estimate from $1.20 to $1.50 per share (about $73 million). Management has not said which new sites are closing or whether these charges will finally end in 2027.